QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

NUVL

QT78Nuvalent, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
123.43
+0.07+0.06%
OverviewShort InterestFilings
NUVLQT78Nuvalent, Inc.·NASDAQ
OverviewShort InterestFilings
123.43+0.06%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own13.88%
Shs Outstand79.00M
Perf Week-0.02%
Market Cap9.07BForward P/E-EPS next Y-4.35Insider Trans0.47%Shs Float-Perf Month22.21%
Enterprise Value8.91BPEG0.72EPS next Q-Inst Own-Short Float-Perf Quarter27.17%
Income-421065833.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y20.27%
Sales-P/B8.26EPS next Y22.91%ROA-33.81%Short Interest-Perf YTD22.71%
Book/sh-0.39P/C-EPS next 5Y-ROE-42.78%52W High123.62 -0.15%Perf Year62.28%
Cash/sh0.13P/FCF-EPS past 3/5Y-ROIC-35.11%52W Low71.13 73.53%Perf 3Y-
Dividend Est.-EV/EBITDA-26.66Sales past 3/5Y-Gross Margin0.00%Volatility0.13% 7.55%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-Oper. Margin0.00%ATR (14)4.16Perf 10Y-
Dividend Ex-Date-Quick Ratio16.14Sales Y/Y TTM-Profit Margin0.00%RSI (14)66.84Recom2.67
Dividend Gr. 3/5Y-Current Ratio16.14EPS Q/Q-SMA2013.75%Beta0.85Target Price132.74
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA5016.84%Rel Volume1.91Prev Close123.36
Employees162LT Debt/Eq-0.06Earnings-SMA20023.83%Avg Volume2.31MPrice123.43
IPO DateJul 29, 2021Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA0.48Volume4,406,924Change0.06%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-10-26DowngradeUBSBuy → Neutral$132 → $124
Jun-10-26DowngradeGuggenheimBuy → Neutral$122 → $124
Jun-10-26DowngradeBarclaysOverweight → Equal Weight$124
Jun-10-26DowngradeTruist SecuritiesBuy → Hold
Jun-10-26DowngradeTD CowenBuy → Hold
Jun-10-26DowngradeWedbushOutperform → Neutral$124
Jun-09-26ReiteratedTruist Financial$140 → $124
Jun-09-26ReiteratedRobert W. Baird$123
Jun-09-26ReiteratedStifel Nicolaus$135 → $124
Jun-09-26ReiteratedH.C. Wainwright$155 → $124
Latest News
Jun-12-26
Jun-12-2607:30AM
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend YieldsBenzinga
Jun-11-26
Jun-11-2603:43PM
Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase InhibitorsSeekingAlpha
Jun-10-26
Jun-10-2611:21AM
TD Cowen Downgrades Nuvalent to Hold, Announces $124 Price TargetBenzinga
10:21AM
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For WednesdayBenzinga
10:09AM
Barclays Downgrades Nuvalent to Equal-Weight, Lowers Price Target to $124Benzinga
09:56AM
Wedbush Downgrades Nuvalent to Neutral, Lowers Price Target to $124Benzinga
09:28AM
UBS Downgrades Nuvalent to Neutral, Lowers Price Target to $124Benzinga
09:21AM
Guggenheim Downgrades Nuvalent to Neutral, Lowers Price Target to $124Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other1076336
Research and Development307218113
Other Operating Expense0-10
Operating Income-414-280-149
Interest Expense0023
Unusual Expense
———
Non-Operating Income (Expense)10-20-23
Net Income Before Taxes-425-260-126
Income Taxes110
Consolidated Net Income-425-261-126
Net Income From Continuing Operations-425-261-126
Net Income-425-261-126
EPS (Recurring)-5.85-3.93-2.17
EPS (Basic, Before Extraordinaries)-5.85-3.93-2.17
EPS (Diluted)-5.85-3.93-2.17
EBITDA-1020-126
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding736658
Market Capitalization7,343——
Operating Lease Expense
———
Insider Trading Volume
$151.04$139.79$128.54$117.30$106.05● Close Price0.00M10.33M20.66M30.98M41.31MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Noci DarleneChief Development OfficerJun 09 '26Option Exercise9.5940,000383,70678,117Jun 11 12:00 AM
Noci DarleneChief Development OfficerJun 09 '26Sale122.8120,0002,456,20058,117Jun 11 12:00 AM
Porter James RichardPresident and CEOJun 08 '26Sale88.5330,0002,656,005324,879Jun 10 12:00 AM
Porter James RichardPresident and CEOJun 08 '26Option Exercise18.9360,0001,135,800354,879Jun 10 12:00 AM
Noci DarleneChief Development OfficerMay 28 '26Sale107.805,500592,92358,117Jun 01 12:00 AM
Noci DarleneChief Development OfficerMay 28 '26Option Exercise27.8511,000306,35086,829Jun 01 12:00 AM
Miller Deborah AnnChief Legal OfficerMay 28 '26Option Exercise6.8911,00075,79072,608Jun 01 12:00 AM
Miller Deborah AnnChief Legal OfficerMay 28 '26Sale107.845,500593,10159,634Jun 01 12:00 AM
Porter James RichardPresident and CEOMay 04 '26Sale101.6930,0003,050,711324,879May 06 12:00 AM
Porter James RichardPresident and CEOMay 04 '26Option Exercise18.9360,0001,135,800354,879May 06 12:00 AM
Balcom AlexandraChief Financial OfficerMay 01 '26Sale99.0011,4301,131,60085,533May 05 12:00 AM
Balcom AlexandraChief Financial OfficerMay 01 '26Option Exercise3.2522,86074,318131,637May 05 12:00 AM
Miller Deborah AnnChief Legal OfficerApr 30 '26Sale99.225,500545,69159,634May 01 12:00 AM
Miller Deborah AnnChief Legal OfficerApr 30 '26Option Exercise6.8911,00075,79078,108May 01 12:00 AM
Noci DarleneChief Development OfficerApr 29 '26Sale99.555,500547,52458,117May 01 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR